{
    "clinical_study": {
        "@rank": "119195", 
        "arm_group": [
            {
                "arm_group_label": "piperacillin/tazobactam", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "imipenem/cilastatin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Neutropenia is very common in patients received hematopoietic stem cell transplantation,\n      with median duration of about 14 days. In 2010 update, IDSA recommended\n      Piperacillin/tazobactam as first-line mono-therapy for febrile patients with neutropenia of\n      high risk. In china, the data of piperacillin/tazobactam for febrile neutropenia after\n      hematopoietic stem cell transplantation is very limited.\n\n      The current study will evaluate the efficacy of piperacillin/tazobactam compared with\n      imipenem/cilastatin for febrile neutropenia after transplantation."
        }, 
        "brief_title": "Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Febrile", 
            "Neutropenia", 
            "Hematopoietic Stem Cell Transplantation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fever", 
                "Neutropenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. Swab culture (skin, pharyngeal, nasal, anus) when administered into laminar flow room\n           after transplantation.\n\n        2. Randomize the febrile patients into 2 groups.\n\n        3. Therapy group receive piperacillin/tazobactam, 4.5g q6h iv. Control group receive\n           imipenem/cilastatin, 0.5g q6h. Duration will be 5-10 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 13-65 years\n\n          -  received Autologous or Allogeneic hematopoietic stem cell transplantation.\n\n          -  ECOG score 0-1.\n\n          -  ICF is available.\n\n        Exclusion Criteria:\n\n          -  Allergic to any therapy drug.\n\n          -  Documented infection before neutropenia.\n\n          -  Renal dysfunction.\n\n          -  Suffering from central nervous system or mental disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "123", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01714570", 
            "org_study_id": "PTZ-20120702"
        }, 
        "intervention": [
            {
                "arm_group_label": "piperacillin/tazobactam", 
                "description": "4.5g q6h, 5-10 days", 
                "intervention_name": "Piperacillin-tazobactam combination product", 
                "intervention_type": "Drug", 
                "other_name": "Tazocin"
            }, 
            {
                "arm_group_label": "imipenem/cilastatin", 
                "description": "0.5g q6h, 5-10 days", 
                "intervention_name": "Imipenem", 
                "intervention_type": "Drug", 
                "other_name": "Tienam"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Piperacillin", 
                "Imipenem", 
                "Penicillanic Acid", 
                "Piperacillin-tazobactam combination product", 
                "Tazobactam"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100853"
                }, 
                "name": "Chinese PLA general hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized, Open Label Study of Piperacillin/Tazobactam Versus Imipenem/Cilastin for Empirical Therapy of Febrile Patients With Neutropenia After Hematopoietic Stem Cell Transplantation", 
        "overall_official": {
            "affiliation": "Employee", 
            "last_name": "wenrong huang, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Resolve of clinical symptoms and signs, without change of therapy.", 
            "measure": "Clinical success rate.", 
            "safety_issue": "No", 
            "time_frame": "3 weeks after beginning of empirical therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01714570"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "Wenrong Huang", 
            "investigator_title": "Associate director, Hematology, Chinese PLA General hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Microbiologic success includes eradication, suspected eradication, and super-infection.\nEradication or Presumed eradication: the baseline pathogens no longer present on the culture performed after completion of treatment. If no way to collect biologic sample(s) after treatment;, e.g. sputum, a presumed eradication will be concluded\nNo eradication: one or more baseline pathogens were persistent\nRelapse: the baseline pathogens transient absence reappeared during the therapy\nAlternative: the baseline pathogens were eradicated, but new ones appeared without any clinical signs and symptoms\nRe-infection: the baseline pathogens were eradicated, but new ones appeared with clinical signs and symptoms.", 
                "measure": "Microbiologic success rate", 
                "safety_issue": "No", 
                "time_frame": "3 weeks after beginning of empirical therapy"
            }, 
            {
                "description": "The number of patients developed unexpected medical information at the 3 weeks after beginning of empirical therapy.", 
                "measure": "Adverse effect", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks after beginning of empirical therapy"
            }, 
            {
                "measure": "Cost of drug and therapy", 
                "safety_issue": "No", 
                "time_frame": "3 weeks after beginning of empirical therapy"
            }
        ], 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese PLA General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}